Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Tumor Infiltrating Lymphocytes (TIL) in Advanced Solid Cancers
NCT03935893Phase 2Active, not recruiting
- Start
- Dec 2019
- Primary completion
- Jun 2037
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous tumor-infiltrating lymphocytes in gastric cancer (GC), colorectal cancer (CRC), pancreatic cancer (PC), sarcoma, mesothelioma. Started Dec 2019; status: active, not recruiting.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)pancreatic cancer (PC)sarcomamesothelioma
Beyond the preview
Go deeper on NCT03935893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03935893.